drugset / Trial / NCT00183677

Brain Energy Metabolism in Individuals With Major Depressive Disorder Receiving Escitalopram

NCT00183677

Phase 4 Completed 97 enrolled Massachusetts General Hospital
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate changes in brain energy metabolism due to treatment with escitalopram in people with major depressive disorder.

Timeline

Start
2003-07
Primary completion
2009-06
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Escitalopram Small molecule 10 mg
Subject Escitalopram Small molecule 20 mg
Subject Escitalopram Small molecule 30 mg

Indications